About Can-Fite
Can-Fite is a company based in Petah Tikva (Israel) founded in 1994 by Pnina Fishman and Ilan Cohn. Can-Fite has raised $25.5 million across 19 funding rounds from investors including Chong Kun Dang Pharmaceutical, Giza Venture Capital and Yozma Group Korea. The company has 5 employees as of December 31, 2024. Can-Fite operates in a competitive market with competitors including Merck, AbbVie, Lilly, Roche and Novo Nordisk, among others.
- Headquarter Petah Tikva, Israel
- Employees 5 as on 31 Dec, 2024
- Founders Pnina Fishman, Ilan Cohn
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Can-Fite Biopharma Ltd.
-
Annual Revenue
$682.83 K (USD)-8.95as on Dec 31, 2024
-
Net Profit
-$8 M (USD)-3.6as on Dec 31, 2024
-
EBITDA
-$8.25 M (USD)0.33as on Dec 31, 2024
-
Total Equity Funding
$25.5 M (USD)
in 19 rounds
-
Latest Funding Round
Not available
-
Investors
Chong Kun Dang Pharmaceutical
& 3 more
-
Employee Count
5
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Can-Fite
Can-Fite is a publicly listed company on the TASE with ticker symbol CANF in Israel, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Funding Insights of Can-Fite
Can-Fite has successfully raised a total of $25.5M across 19 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Can-Fite
Can-Fite has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include Chong Kun Dang Pharmaceutical, Giza Venture Capital and Yozma Group Korea.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
VC firm investing in seed & early stage companies in Israel & the US
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Traditional Korean pharma company with a portfolio of immunosuppressants, anti-cancers and antibiotics
|
Locked | Locked | Locked |
Investor details for Can-Fite
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Can-Fite
Investment portfolio details for Can-Fite
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Can-Fite
Detailed financials for Can-Fite
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Can-Fite Comparisons
Peer comparison for Can-Fite
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Can-Fite
Can-Fite operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Merck, AbbVie, Lilly, Roche and Novo Nordisk, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Pharmaceutical products are manufactured and marketed worldwide.
|
|
| Locked | Locked | Locked |
Biopharmaceutical research and drug development are conducted globally by AbbVie.
|
|
| Locked | Locked | Locked |
Traditional pharmaceutical medicines are developed for multiple health fields.
|
|
| Locked | Locked | Locked |
Pharmaceuticals and diagnostics kits are developed for various diseases.
|
|
| Locked | Locked | Locked |
Drugs for diabetes, obesity, hemophilia, and hormone therapy are manufactured.
|
|
| Locked | Locked | Locked |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed.
|
Detailed competitors of Can-Fite
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Can-Fite
Complete news archive for Can-Fite
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Can-Fite
Can-Fite was founded in 1994 and raised its 1st funding round 7 years after it was founded.
Can-Fite is headquartered in Petah Tikva, Israel. It is registered at Petah Tikva, Central District, Israel.
Pnina Fishman is the current CEO of Can-Fite. They have also founded this company.
Can-Fite is a funded company, having raised a total of $25.5M across 19 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Can-Fite is 5.
Annual revenue of Can-Fite is $682.83K as on Dec 31, 2024.
Can-Fite was founded in 1994 and is headquartered in Petah Tikva, Israel. Operations are centered on the development of small molecule therapeutics targeting autoimmune-inflammatory diseases and cancer. Leadership is provided by co-founders Pnina Fishman as CEO and Ilan Cohn. Focus is placed on advancing drug candidates through preclinical and clinical stages in the biotechnology sector, with activities conducted primarily in Israel.
Can-Fite's top competitors include Merck, Roivant Sciences and Amgen.
Yes, Can-Fite is publicly traded on TASE under the ticker symbol CANF.
Can-Fite has 4 investors. Key investors include Chong Kun Dang Pharmaceutical, Giza Venture Capital, Yozma Group Korea, and Ascend Technology Ventures.
The ticker symbol of Can-Fite is CANF on TASE.